Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 6/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18608229 | 0.88 | CYP1A2 (0.44) | CNR2AGTR2DRD1DRD3 | |
| SCHEMBL17773502 | 0.86 | DRD3 (0.40) | DRD1DRD3 | |
| SCHEMBL8964420 | 0.86 | AGTR2 (0.57) | AGTR2AGTR1 | |
| SCHEMBL8964415 | 0.86 | AGTR2 (0.57) | AGTR2AGTR1 | |
| SCHEMBL433767 | 0.83 | AGTR2 (0.56) | AGTR2AGTR1 | |
| SCHEMBL421422 | 0.83 | AGTR2 (0.56) | AGTR2AGTR1 | |
| Hydrochloric Acid SCHEMBL23780713 | 0.82 | AGTR2 (0.55) | AGTR2AGTR1 | |
| Hydrochloric Acid SCHEMBL23780714 | 0.82 | AGTR2 (0.55) | AGTR2AGTR1 | |
| SCHEMBL10073016 | 0.82 | DRD1 (0.40) | CNR2DRD1DRD3 | |
| SCHEMBL21602706 | 0.79 | MEN1 (0.35) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714224-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2017-07-25 | — | — | US | disclosed |
| EP-3081557-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | Novartis AG (CH) | 2016-10-19 | — | — | EP | disclosed |
| US-20160145213-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2016-05-26 | — | — | US | disclosed |
| EP-2595960-B1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | NOVARTIS AG (CH) | 2016-02-24 | — | — | EP | disclosed |
| US-9162985-B2 | Salts and solvates of a tetrahydroisoquinoline derivative | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-10-20 | — | — | US | disclosed |
| US-20150105422-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-04-16 | — | — | US | disclosed |
| US-8927575-B2 | Salts and solvates of a tetrahydroisoquinoline derivative | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-01-06 | — | — | US | disclosed |
| US-20140080865-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-03-20 | — | — | US | disclosed |
| WO-2012010843-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080865-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SUDS3, REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CNR2 2068/4885AGTR2 126/4885AGTR1 181/4885 |
| US-20150105422-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SUDS3, REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CNR2 2068/4885AGTR2 126/4885AGTR1 181/4885 |
| US-20160145213-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | AGTR2, AGTR1, AGT | CNR2 48/4885AGTR2 1/4885AGTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.